A Multicenter Randomized Controlled Trial of Best Available

Recruiting

18 years - 55 years

All

Phase N/A

4 participants needed

1 Location

Brief description of study

The purpose of this study is to compare efficacy and safety of Autologous Hematopoietic Stem Cell Transplant (AHSCT) to best available therapy (BAT) in relapsing MS. Best available therapy is referring to the best available medications that are used to treat MS. Patients who agree to participate in the experimental treatment study will be randomly chosen (like a coin flip) to have an AHSCT or BAT. Neither you nor your doctor are able to decide which treatment you will receive. In addition, patients interested in participating must have permission from their insurance company to enter the trial.

Detailed description of study

card43

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Multiple Sclerosis
Age: 18 years - 55 years
Gender: All

Updated on 22 Aug 2024. Study ID: 20-0339

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

View email

Phone

View phone

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Please provide your preferred way of contact

Other language

By Submitting your information, you agree that your details may be shared with the selected study site and handled in accordance with this Website's Privacy Policy (see link in footer). You may be contacted by email, text message, or phone regarding this study and other research opportunities that may be of interested to you. You can unsubscribe from these communications at any time. Message and data rates may apply.

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.